PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma

Leukemia

Volumn 29, Issue 10, 2015, Pages 2110-2113

  Paiva, B ^a,b,c   Azpilikueta, A ^b   Puig, N ^d   Ocio, E M ^d   Sharma, R ^e   Oyajobi, B O ^e   Labiano, S ^b   San Segundo, L ^d   Rodriguez, A ^c   Aires Mejia, I ^d   Rodriguez, I ^b   Escalante, F ^f   De Coca, A G ^g   Barez, A ^h   San Miguel, J F ^a,b,c   Melero, I ^a,b,c  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c Recinto de Complejo Hospitalario de Navarra   (Spain)

^d HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f HOSPITAL DE LEÓN   (Spain)

^g HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^h HOSPITAL NUESTRA SEÑORA DE SONSOLES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY RPMP1-14; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG; PDCD1 PROTEIN, HUMAN;

DRUG TARGETING; HUMAN; LETTER; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELAPSE; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE MARROW; C57BL MOUSE; CANCER STAGING; CASE CONTROL STUDY; CELL CULTURE; COMPARATIVE STUDY; FEMALE; FOLLOW UP; IMMUNOPHENOTYPING; METABOLISM; MORTALITY; MOUSE; NATURAL KILLER CELL; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; STEM CELL; SURVIVAL RATE; T LYMPHOCYTE; TUMOR RECURRENCE;

ANIMALS; ANTIGENS, CD274; BONE MARROW; CASE-CONTROL STUDIES; CELLS, CULTURED; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOPHENOTYPING; KILLER CELLS, NATURAL; MICE; MICE, INBRED C57BL; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; PROSPECTIVE STUDIES; STEM CELLS; SURVIVAL RATE; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 84943587397     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.79     Document Type: Letter

References (15)

1. Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R, et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia 2014; 28: 525-542
2. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-264
3. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515: 568-571
4. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515: 563-567
5. Rosenblatt J, Avivi I, Vasir B, Uhl L, Katz T, Somaiya P, et al. Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation. ASH Annual Meeting Abstracts 2012; 120: 578
6. Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, Hetuin D, et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 2007; 110: 296-304
7. Tamura H, Ishibashi M, Yamashita T, Tanosaki S, Okuyama N, Kondo A, et al. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia 2013; 27: 464-472
8. Benson Jr. DM, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010; 116: 2286-2294
9. Hallett WH, Jing W, Drobyski WR, Johnson BD. Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade. Biol Blood Marrow Transpl 2011; 17: 1133-1145
10. Rosenblatt J, Avivi I, Vasir B, Uhl L, Munshi NC, Katz T, et al. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res 2013; 19: 3640-3648
11. Kearl TJ, Jing W, Gershan JA, Johnson BD. Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma. J Immunol 2013; 190: 5620-5628
12. Paiva B, Vidriales MB, Rosinol L, Martinez-Lopez J, Mateos MV, Ocio EM, et al. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-Term disease control. Leukemia 2013; 27: 2056-2061
13. Radl J, Croese JW, Zurcher C, Van den Enden-Vieveen MH, de Leeuw AM. Animal model of human disease. Multiple myeloma. Am J Pathol 1988; 132: 593-597
14. Murillo O, Arina A, Hervas-Stubbs S, Gupta A, McCluskey B, Dubrot J, et al. Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma. Clin Cancer Res. 2008; 14: 6895-6906
15. Melero I, Grimaldi AM, Perez-Gracia JL, Ascierto PA. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res 2013; 19: 997-1008